Aquestive Therapeutics (Aquestive Therapeutics) EV-to-Revenue : 7.43 (As of Apr. 29, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aquestive Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aquestive Therapeutics's enterprise value is $375.62 Mil. Aquestive Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $50.58 Mil. Therefore, Aquestive Therapeutics's EV-to-Revenue for today is 7.43.

The historical rank and industry rank for Aquestive Therapeutics's EV-to-Revenue or its related term are showing as below:

AQST' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.05 Med: 2.96 Max: 8.29
Current: 7.43

During the past 8 years, the highest EV-to-Revenue of Aquestive Therapeutics was 8.29. The lowest was 1.05. And the median was 2.96.

AQST's EV-to-Revenue is ranked worse than
84.02% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs AQST: 7.43

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-29), Aquestive Therapeutics's stock price is $4.07. Aquestive Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.78. Therefore, Aquestive Therapeutics's PS Ratio for today is 5.22.

Aquestive Therapeutics EV-to-Revenue Historical Data

The historical data trend for Aquestive Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aquestive Therapeutics EV-to-Revenue Chart

Aquestive Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

3.92

4.22

3.71

1.67

2.92

Aquestive Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															1.67	1.83	2.67	2.54	2.92

Competitive Comparison of Aquestive Therapeutics's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aquestive Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aquestive Therapeutics's EV-to-Revenue falls into.

Aquestive Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aquestive Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	375.616	/	50.583
	=	7.43

Aquestive Therapeutics's current Enterprise Value is $375.62 Mil.
Aquestive Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $50.58 Mil.

Aquestive Therapeutics (NAS:AQST) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aquestive Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	4.07	/	0.779
	=	5.22

Aquestive Therapeutics's share price for today is $4.07.
Aquestive Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.78.

Aquestive Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aquestive Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aquestive Therapeutics (Aquestive Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Technology Drive, Warren, NJ, USA, 07059

Website

https://www.aquestive.com

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Executives

Carl N Kraus	officer: Chief Medical Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Stephen Wargacki	officer: SVP, Research & Development	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Cassie Jung	officer: SVP, Operations	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Kenneth Truitt	officer: Chief Medical Officer	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Timothy E Morris	director	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Peter E. Boyd	officer: SVP-Operations/Value Delivery	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Lori J Braender	officer: SVP, General Counsel	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Daniel Barber	officer: SVP-Chief Strategy/Dev Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alexander Mark Schobel	director, officer: Chief Innovation/Tech Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Julie Krop	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Marco Taglietti	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Toth A Ernest Jr	officer: Interim CFO
John T. Maxwell	officer: SVP-Chief Financial Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Keith J Kendall	director, officer: President and CEO	30 TECHNOLOGY DRIVE, WARREN NJ 07059
James S Scibetta	director	C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154